www.g4media.ro/medicamentele-populare-pentru-slabi

Recent research indicates that GLP-1 medications, such as semaglutide and tirzepatide, may significantly lower the risk of developing type 2 diabetes and reduce mortality rates among obese individuals with prediabetes. The study found a 31% reduction in diabetes risk and a 41% decrease in overall mortality compared to metformin treatment. Additionally, GLP-1 medications were associated with lower risks of stroke, heart attack, and heart failure. While the findings are promising, they remain preliminary and require further validation through rigorous scientific evaluation. Experts suggest that early intervention with GLP-1 treatments could be beneficial for prediabetic patients.